EMDR and Ketamine Infusion Therapy: What Does the Research Say?

One of the more striking developments in trauma treatment over the past decade has been the use of ketamine, an anaesthetic drug, at low doses for depression and PTSD. Given intravenously under medical supervision, it can lift symptoms within hours rather than weeks. A growing number of clinics now pair these infusions with psychotherapy, and EMDR has become one of the more common partners, to the point where a named approach, Ketamine Assisted EMDR Therapy, now exists.

The reasoning behind the pairing is genuinely interesting. Ketamine appears to open a temporary window of heightened neuroplasticity, a period in which the brain may be unusually able to form new connections and update old patterns. If that window is real, then filling it with a therapy designed to reprocess traumatic memories seems a sensible use of it. EMDR fits the setting particularly well, because it does not require someone to give a detailed verbal account of what happened, which is difficult during an altered state.

So does it work? The early evidence looked encouraging. A meta-analysis by Philipp-Muller and colleagues, published in the Journal of Clinical Psychiatry (2023), pooled four studies combining ketamine with psychotherapy for PTSD and found large improvements on standard symptom measures. But it involved just 34 patients in total, and the authors rated two of the four studies as low quality and two as moderate.

More recent work complicates the picture considerably. A large observational study by Moore and colleagues, published in the Journal of Affective Disorders (2025), compared hundreds of people receiving ketamine alone against those receiving ketamine plus psychotherapy. Both groups improved substantially, with the same pattern of rapid early gains followed by stabilisation. Crucially, there was no significant difference between them. The authors suggest ketamine's effects may simply be strong enough that added psychotherapy does not measurably improve short-term outcomes.

That is an awkward finding for the combined model, and worth stating plainly rather than skipping past. It does not disprove the approach, since the study was observational, looked at the acute phase only, and did not isolate EMDR specifically. Longer-term outcomes, particularly whether therapy helps gains last once infusions stop, remain genuinely open. A dedicated paper on Ketamine Assisted EMDR Therapy appeared in the European Journal of Psychotraumatology in 2025, so the specific question is now being studied.

Two practical points matter for UK readers. Ketamine is a controlled drug with recognised harms, and this is specialist medical treatment requiring proper assessment and supervision, not something to arrange casually. And in the UK it is not a routine PTSD treatment: limited NHS interventional psychiatry services offer it for treatment-resistant depression, while its use for PTSD remains off-label and largely confined to private clinics and research settings.

The honest summary is that the theory is plausible, the early results are interesting, and the evidence is nowhere near settled. Anyone considering this should discuss it with a doctor rather than a website.